CA2442969A1

CA2442969A1 - Methods for selective immunomodulation using pimecrolimus

Methods for selective immunomodulation using pimecrolimus Download PDF

Info

Publication number: CA2442969A1
Authority: CA; Canada
Prior art keywords: pimecrolimus; treatment; asthma; inflammatory disorder; less
Prior art date: 2001-05-09
Legal status : Abandoned

Application number

CA002442969A

Other languages

English (en)

French (fr)

Inventor

Salah-Dine Chibout

Andre Cordier

Jeanne Kehren

Henrietta Denise Moore

Current Assignee

Novartis AG

Original Assignee

Individual

Priority date

2001-05-09

Filing date

2002-05-09

Publication date

2002-11-14

2002-05-09 Application filed by Individual filed Critical Individual

2002-11-14 Publication of CA2442969A1 publication Critical patent/CA2442969A1/en

Status Abandoned legal-status Critical Current

Links

229960005330 pimecrolimus Drugs 0.000 title claims abstract description 284
238000000034 method Methods 0.000 title claims abstract description 95
KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 title claims abstract 26
230000002519 immonomodulatory effect Effects 0.000 title abstract description 4
208000006673 asthma Diseases 0.000 claims abstract description 165
208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 111
230000000694 effects Effects 0.000 claims abstract description 107
230000009885 systemic effect Effects 0.000 claims abstract description 72
208000027866 inflammatory disease Diseases 0.000 claims abstract description 36
238000011282 treatment Methods 0.000 claims description 167
239000003814 drug Substances 0.000 claims description 117
229940079593 drug Drugs 0.000 claims description 94
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 61
108010036949 Cyclosporine Proteins 0.000 claims description 61
230000001506 immunosuppresive effect Effects 0.000 claims description 56
229930105110 Cyclosporin A Natural products 0.000 claims description 52
229960001265 ciclosporin Drugs 0.000 claims description 52
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
241000282414 Homo sapiens Species 0.000 claims description 43
239000003862 glucocorticoid Substances 0.000 claims description 42
239000003246 corticosteroid Substances 0.000 claims description 35
206010062016 Immunosuppression Diseases 0.000 claims description 26
208000024891 symptom Diseases 0.000 claims description 26
230000036765 blood level Effects 0.000 claims description 24
230000002757 inflammatory effect Effects 0.000 claims description 19
230000002411 adverse Effects 0.000 claims description 18
238000002360 preparation method Methods 0.000 claims description 18
206010028980 Neoplasm Diseases 0.000 claims description 17
208000001388 Opportunistic Infections Diseases 0.000 claims description 17
229960002170 azathioprine Drugs 0.000 claims description 17
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 17
230000001580 bacterial effect Effects 0.000 claims description 16
230000002265 prevention Effects 0.000 claims description 16
230000003612 virological effect Effects 0.000 claims description 16
108010002350 Interleukin-2 Proteins 0.000 claims description 15
208000030289 Lymphoproliferative disease Diseases 0.000 claims description 15
244000052616 bacterial pathogen Species 0.000 claims description 15
244000053095 fungal pathogen Species 0.000 claims description 15
230000036210 malignancy Effects 0.000 claims description 15
238000003571 reporter gene assay Methods 0.000 claims description 15
244000052613 viral pathogen Species 0.000 claims description 15
206010025323 Lymphomas Diseases 0.000 claims description 14
229960000265 cromoglicic acid Drugs 0.000 claims description 9
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 9
239000000443 aerosol Substances 0.000 claims description 8
238000001802 infusion Methods 0.000 claims description 7
239000000829 suppository Substances 0.000 claims description 5
238000002626 targeted therapy Methods 0.000 claims description 5
241000792859 Enema Species 0.000 claims description 4
239000007920 enema Substances 0.000 claims description 4
229940095399 enema Drugs 0.000 claims description 4
241000282412 Homo Species 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
229960000598 infliximab Drugs 0.000 claims description 3
230000037317 transdermal delivery Effects 0.000 claims description 3
239000000695 adrenergic alpha-agonist Substances 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
239000006194 liquid suspension Substances 0.000 claims description 2
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
229940113720 aminosalicylate Drugs 0.000 claims 1
239000006193 liquid solution Substances 0.000 claims 1
210000000981 epithelium Anatomy 0.000 abstract description 37
KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 261
241000699670 Mus sp. Species 0.000 description 50
239000003018 immunosuppressive agent Substances 0.000 description 46
229960003444 immunosuppressant agent Drugs 0.000 description 45
239000008280 blood Substances 0.000 description 43
210000004369 blood Anatomy 0.000 description 42
201000010099 disease Diseases 0.000 description 40
230000004054 inflammatory process Effects 0.000 description 39
108090000623 proteins and genes Proteins 0.000 description 37
206010061218 Inflammation Diseases 0.000 description 36
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 36
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 35
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 34
230000001861 immunosuppressant effect Effects 0.000 description 32
210000001744 T-lymphocyte Anatomy 0.000 description 30
239000000203 mixture Substances 0.000 description 30
239000000902 placebo Substances 0.000 description 30
229940068196 placebo Drugs 0.000 description 30
238000011579 SCID mouse model Methods 0.000 description 29
206010009900 Colitis ulcerative Diseases 0.000 description 28
208000011231 Crohn disease Diseases 0.000 description 28
201000006704 Ulcerative Colitis Diseases 0.000 description 28
210000004027 cell Anatomy 0.000 description 27
229940037128 systemic glucocorticoids Drugs 0.000 description 26
230000003110 anti-inflammatory effect Effects 0.000 description 24
229960001334 corticosteroids Drugs 0.000 description 24
238000009472 formulation Methods 0.000 description 23
210000004698 lymphocyte Anatomy 0.000 description 23
210000003491 skin Anatomy 0.000 description 22
230000014509 gene expression Effects 0.000 description 21
230000001965 increasing effect Effects 0.000 description 21
230000037396 body weight Effects 0.000 description 20
230000001225 therapeutic effect Effects 0.000 description 20
210000004072 lung Anatomy 0.000 description 18
210000001519 tissue Anatomy 0.000 description 18
206010009887 colitis Diseases 0.000 description 17
210000004877 mucosa Anatomy 0.000 description 17
210000000952 spleen Anatomy 0.000 description 17
150000003431 steroids Chemical class 0.000 description 17
230000009471 action Effects 0.000 description 16
210000001072 colon Anatomy 0.000 description 16
210000000440 neutrophil Anatomy 0.000 description 16
210000003979 eosinophil Anatomy 0.000 description 15
210000001035 gastrointestinal tract Anatomy 0.000 description 15
229960000890 hydrocortisone Drugs 0.000 description 15
210000002966 serum Anatomy 0.000 description 15
102000014702 Haptoglobin Human genes 0.000 description 13
108050005077 Haptoglobin Proteins 0.000 description 13
239000008194 pharmaceutical composition Substances 0.000 description 13
102000000588 Interleukin-2 Human genes 0.000 description 12
201000004681 Psoriasis Diseases 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
230000000699 topical effect Effects 0.000 description 12
238000003556 assay Methods 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
150000001875 compounds Chemical class 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
230000001684 chronic effect Effects 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
238000011269 treatment regimen Methods 0.000 description 10
102000004127 Cytokines Human genes 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
238000010171 animal model Methods 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
230000001105 regulatory effect Effects 0.000 description 9
239000003826 tablet Substances 0.000 description 9
201000004624 Dermatitis Diseases 0.000 description 8
230000000172 allergic effect Effects 0.000 description 8
239000003242 anti bacterial agent Substances 0.000 description 8
229940088710 antibiotic agent Drugs 0.000 description 8
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
208000010668 atopic eczema Diseases 0.000 description 8
230000008901 benefit Effects 0.000 description 8
210000004969 inflammatory cell Anatomy 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000009467 reduction Effects 0.000 description 8
230000004044 response Effects 0.000 description 8
206010006482 Bronchospasm Diseases 0.000 description 7
206010014950 Eosinophilia Diseases 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
241000700159 Rattus Species 0.000 description 7
239000013566 allergen Substances 0.000 description 7
239000002260 anti-inflammatory agent Substances 0.000 description 7
239000006285 cell suspension Substances 0.000 description 7
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
210000003630 histaminocyte Anatomy 0.000 description 7
230000007774 longterm Effects 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 7
229960004963 mesalazine Drugs 0.000 description 7
238000010172 mouse model Methods 0.000 description 7
230000003204 osmotic effect Effects 0.000 description 7
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 7
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 7
102100032367 C-C motif chemokine 5 Human genes 0.000 description 6
108010055166 Chemokine CCL5 Proteins 0.000 description 6
206010012442 Dermatitis contact Diseases 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
230000001154 acute effect Effects 0.000 description 6
230000007885 bronchoconstriction Effects 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
210000000038 chest Anatomy 0.000 description 6
229960003957 dexamethasone Drugs 0.000 description 6
238000009826 distribution Methods 0.000 description 6
230000035874 hyperreactivity Effects 0.000 description 6
230000008595 infiltration Effects 0.000 description 6
238000001764 infiltration Methods 0.000 description 6
210000000265 leukocyte Anatomy 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
210000003097 mucus Anatomy 0.000 description 6
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 6
239000007962 solid dispersion Substances 0.000 description 6
238000007920 subcutaneous administration Methods 0.000 description 6
230000001629 suppression Effects 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
208000000884 Airway Obstruction Diseases 0.000 description 5
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
108010036941 Cyclosporins Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 5
108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
230000004913 activation Effects 0.000 description 5
208000002029 allergic contact dermatitis Diseases 0.000 description 5
229940121363 anti-inflammatory agent Drugs 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
229940124630 bronchodilator Drugs 0.000 description 5
208000023819 chronic asthma Diseases 0.000 description 5
229930182912 cyclosporin Natural products 0.000 description 5
230000003111 delayed effect Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
210000001165 lymph node Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000005259 measurement Methods 0.000 description 5
230000005012 migration Effects 0.000 description 5
238000013508 migration Methods 0.000 description 5
230000000414 obstructive effect Effects 0.000 description 5
229960004618 prednisone Drugs 0.000 description 5
239000000047 product Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
238000012546 transfer Methods 0.000 description 5
206010048998 Acute phase reaction Diseases 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
230000004658 acute-phase response Effects 0.000 description 4
239000000808 adrenergic beta-agonist Substances 0.000 description 4
201000009961 allergic asthma Diseases 0.000 description 4
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 4
239000000168 bronchodilator agent Substances 0.000 description 4
230000008859 change Effects 0.000 description 4
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
230000003828 downregulation Effects 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000006870 function Effects 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
230000033001 locomotion Effects 0.000 description 4
239000003120 macrolide antibiotic agent Substances 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
229940046781 other immunosuppressants in atc Drugs 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
229960001967 tacrolimus Drugs 0.000 description 4
238000002054 transplantation Methods 0.000 description 4
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 3
206010003645 Atopy Diseases 0.000 description 3
-1 BRETNINE Chemical compound 0.000 description 3
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 3
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 3
208000017667 Chronic Disease Diseases 0.000 description 3
102000001493 Cyclophilins Human genes 0.000 description 3
108010068682 Cyclophilins Proteins 0.000 description 3
206010012438 Dermatitis atopic Diseases 0.000 description 3
206010012735 Diarrhoea Diseases 0.000 description 3
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
108010016648 Immunophilins Proteins 0.000 description 3
102000000521 Immunophilins Human genes 0.000 description 3
108090000978 Interleukin-4 Proteins 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
206010029379 Neutrophilia Diseases 0.000 description 3
108010035766 P-Selectin Proteins 0.000 description 3
102100023472 P-selectin Human genes 0.000 description 3
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 3
206010037660 Pyrexia Diseases 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
208000037656 Respiratory Sounds Diseases 0.000 description 3
102100040247 Tumor necrosis factor Human genes 0.000 description 3
206010047924 Wheezing Diseases 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
210000005091 airway smooth muscle Anatomy 0.000 description 3
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
230000004075 alteration Effects 0.000 description 3
229960003556 aminophylline Drugs 0.000 description 3
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
208000007502 anemia Diseases 0.000 description 3
201000008937 atopic dermatitis Diseases 0.000 description 3
206010006451 bronchitis Diseases 0.000 description 3
230000007883 bronchodilation Effects 0.000 description 3
229940064332 cortef Drugs 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000000994 depressogenic effect Effects 0.000 description 3
WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 3
238000011161 development Methods 0.000 description 3
BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
229940088679 drug related substance Drugs 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
229960000676 flunisolide Drugs 0.000 description 3
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
239000007789 gas Substances 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
230000028993 immune response Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000004941 influx Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
229940057948 magnesium stearate Drugs 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000008693 nausea Effects 0.000 description 3
230000007170 pathology Effects 0.000 description 3
230000037361 pathway Effects 0.000 description 3
206010035653 pneumoconiosis Diseases 0.000 description 3
229920001993 poloxamer 188 Polymers 0.000 description 3
229940044519 poloxamer 188 Drugs 0.000 description 3
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000001185 psoriatic effect Effects 0.000 description 3
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
238000004062 sedimentation Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
229960000278 theophylline Drugs 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 2
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
208000005223 Alkalosis Diseases 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
206010066091 Bronchial Hyperreactivity Diseases 0.000 description 2
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
102000004631 Calcineurin Human genes 0.000 description 2
108010042955 Calcineurin Proteins 0.000 description 2
208000002177 Cataract Diseases 0.000 description 2
ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
208000000059 Dyspnea Diseases 0.000 description 2
206010013975 Dyspnoeas Diseases 0.000 description 2
208000010201 Exanthema Diseases 0.000 description 2
206010051841 Exposure to allergen Diseases 0.000 description 2
WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
206010053759 Growth retardation Diseases 0.000 description 2
MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
108090001007 Interleukin-8 Proteins 0.000 description 2
102000004890 Interleukin-8 Human genes 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
108010092694 L-Selectin Proteins 0.000 description 2
102100033467 L-selectin Human genes 0.000 description 2
102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
102000004473 OX40 Ligand Human genes 0.000 description 2
108010042215 OX40 Ligand Proteins 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
101100433966 Rattus norvegicus Acd gene Proteins 0.000 description 2
208000005279 Status Asthmaticus Diseases 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
206010043087 Tachyphylaxis Diseases 0.000 description 2
102000003938 Thromboxane Receptors Human genes 0.000 description 2
108090000300 Thromboxane Receptors Proteins 0.000 description 2
TZIZWYVVGLXXFV-FLRHRWPCSA-N Triamcinolone hexacetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)CC(C)(C)C)[C@@]1(C)C[C@@H]2O TZIZWYVVGLXXFV-FLRHRWPCSA-N 0.000 description 2
FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 2
229920002877 acrylic styrene acrylonitrile Polymers 0.000 description 2
208000024716 acute asthma Diseases 0.000 description 2
230000009798 acute exacerbation Effects 0.000 description 2
208000037883 airway inflammation Diseases 0.000 description 2
DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
229960003099 amcinonide Drugs 0.000 description 2
ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 2
ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 2
239000011324 bead Substances 0.000 description 2
SOQJPQZCPBDOMF-YCUXZELOSA-N betamethasone benzoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@@H]1C)C(=O)CO)C(=O)C1=CC=CC=C1 SOQJPQZCPBDOMF-YCUXZELOSA-N 0.000 description 2
229960001102 betamethasone dipropionate Drugs 0.000 description 2
CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 2
229960005354 betamethasone sodium phosphate Drugs 0.000 description 2
PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 2
229960004311 betamethasone valerate Drugs 0.000 description 2
SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229960004620 bitolterol Drugs 0.000 description 2
FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
230000036427 bronchial hyperreactivity Effects 0.000 description 2
239000004044 bronchoconstricting agent Substances 0.000 description 2
230000003435 bronchoconstrictive effect Effects 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
229960003405 ciprofloxacin Drugs 0.000 description 2
CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 2
SXYZQZLHAIHKKY-GSTUPEFVSA-N clocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O SXYZQZLHAIHKKY-GSTUPEFVSA-N 0.000 description 2
238000012321 colectomy Methods 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
229960003290 cortisone acetate Drugs 0.000 description 2
238000011262 co‐therapy Methods 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000008021 deposition Effects 0.000 description 2
VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000008298 dragée Substances 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
229940020485 elidel Drugs 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
201000005884 exanthem Diseases 0.000 description 2
238000010195 expression analysis Methods 0.000 description 2
SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 2
238000004868 gas analysis Methods 0.000 description 2
238000011223 gene expression profiling Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
231100000001 growth retardation Toxicity 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
230000003434 inspiratory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
201000010659 intrinsic asthma Diseases 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
238000009533 lab test Methods 0.000 description 2
108010072713 leukotriene A4 hydrolase Proteins 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000004199 lung function Effects 0.000 description 2
229940041033 macrolides Drugs 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229960001428 mercaptopurine Drugs 0.000 description 2
PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 2
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
229960002259 nedocromil sodium Drugs 0.000 description 2
JQEKDNLKIVGXAU-UHFFFAOYSA-L nedocromil sodium Chemical compound [Na+].[Na+].CCN1C(C([O-])=O)=CC(=O)C2=C1C(CCC)=C1OC(C([O-])=O)=CC(=O)C1=C2 JQEKDNLKIVGXAU-UHFFFAOYSA-L 0.000 description 2
230000031990 negative regulation of inflammatory response Effects 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
230000008569 process Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
201000009732 pulmonary eosinophilia Diseases 0.000 description 2
238000009613 pulmonary function test Methods 0.000 description 2
206010037844 rash Diseases 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000005096 rolling process Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
FKUGSGSUEMPKIL-UHFFFAOYSA-M sodium butanedioic acid dihydrogen phosphate Chemical compound P(=O)([O-])(O)O.C(CCC(=O)O)(=O)O.[Na+] FKUGSGSUEMPKIL-UHFFFAOYSA-M 0.000 description 2
GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical group C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 2
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
229960001940 sulfasalazine Drugs 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
210000004876 tela submucosa Anatomy 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000008719 thickening Effects 0.000 description 2
229960002117 triamcinolone acetonide Drugs 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
206010000364 Accessory muscle Diseases 0.000 description 1
208000013824 Acidemia Diseases 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
208000037874 Asthma exacerbation Diseases 0.000 description 1
206010003557 Asthma exercise induced Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
206010006473 Bronchopulmonary aspergillosis Diseases 0.000 description 1
206010006582 Bundle branch block right Diseases 0.000 description 1
206010006578 Bundle-Branch Block Diseases 0.000 description 1
208000007596 Byssinosis Diseases 0.000 description 1
108700012434 CCL3 Proteins 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
241000272165 Charadriidae Species 0.000 description 1
102000000013 Chemokine CCL3 Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
241000193163 Clostridioides difficile Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000001187 Collagen Type III Human genes 0.000 description 1
108010069502 Collagen Type III Proteins 0.000 description 1
102000012432 Collagen Type V Human genes 0.000 description 1
108010022514 Collagen Type V Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920001076 Cutan Polymers 0.000 description 1
102000006312 Cyclin D2 Human genes 0.000 description 1
108010058544 Cyclin D2 Proteins 0.000 description 1
102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
102100028471 Eosinophil peroxidase Human genes 0.000 description 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
101710139422 Eotaxin Proteins 0.000 description 1
102100023688 Eotaxin Human genes 0.000 description 1
208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
208000034347 Faecal incontinence Diseases 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
108010001517 Galectin 3 Proteins 0.000 description 1
102100039558 Galectin-3 Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000006587 Glutathione peroxidase Human genes 0.000 description 1
108700016172 Glutathione peroxidases Proteins 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
108010061486 HLA-B27 Antigen Proteins 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
206010019851 Hepatotoxicity Diseases 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
102100022339 Integrin alpha-L Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
102000003815 Interleukin-11 Human genes 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102100023012 Kallistatin Human genes 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
108010093008 Kinins Proteins 0.000 description 1
102000002397 Kinins Human genes 0.000 description 1
102000000428 Lactate Dehydrogenases Human genes 0.000 description 1
108010080864 Lactate Dehydrogenases Proteins 0.000 description 1
206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
206010024774 Localised infection Diseases 0.000 description 1
201000009324 Loeffler syndrome Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000003898 Mediastinal Emphysema Diseases 0.000 description 1
GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 1
101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 1
101100433965 Mus musculus Acd gene Proteins 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
102000003896 Myeloperoxidases Human genes 0.000 description 1
108090000235 Myeloperoxidases Proteins 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010030111 Oedema mucosal Diseases 0.000 description 1
102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
241000157426 Pernis Species 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
206010050184 Pneumomediastinum Diseases 0.000 description 1
LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
206010037180 Psychiatric symptoms Diseases 0.000 description 1
208000004430 Pulmonary Aspergillosis Diseases 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010070774 Respiratory tract oedema Diseases 0.000 description 1
208000036284 Rhinitis seasonal Diseases 0.000 description 1
206010039109 Rhonchi Diseases 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
241000242583 Scyphozoa Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000014604 Specific Language disease Diseases 0.000 description 1
206010042464 Suicide attempt Diseases 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
102100023132 Transcription factor Jun Human genes 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 description 1
206010065258 Tropical eosinophilia Diseases 0.000 description 1
206010045240 Type I hypersensitivity Diseases 0.000 description 1
206010046306 Upper respiratory tract infection Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
208000010399 Wasting Syndrome Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
229940033350 aclovate Drugs 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
230000001780 adrenocortical effect Effects 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
239000013567 aeroallergen Substances 0.000 description 1
238000011292 agonist therapy Methods 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
210000001552 airway epithelial cell Anatomy 0.000 description 1
230000010085 airway hyperresponsiveness Effects 0.000 description 1
229960004229 alclometasone dipropionate Drugs 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
208000028462 aluminosis Diseases 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
208000010123 anthracosis Diseases 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
201000007201 aphasia Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229940087508 aristospan Drugs 0.000 description 1
238000003491 array Methods 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
229940127225 asthma medication Drugs 0.000 description 1
208000010216 atopic IgE responsiveness Diseases 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
238000002555 auscultation Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229960000870 betamethasone benzoate Drugs 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
229950010231 brequinar Drugs 0.000 description 1
PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
238000011685 brown norway rat Methods 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
229940087110 celestone Drugs 0.000 description 1
229940079135 celestone soluspan Drugs 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
231100000749 chronicity Toxicity 0.000 description 1
210000003040 circulating cell Anatomy 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
229960004703 clobetasol propionate Drugs 0.000 description 1
229960001357 clocortolone pivalate Drugs 0.000 description 1
229940070397 cloderm Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
229960003950 combination of corticosteroids Drugs 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000000470 constituent Substances 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
229940069235 cordran Drugs 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 description 1
ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
229940026692 decadron Drugs 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000001934 delay Effects 0.000 description 1
229940027008 deltasone Drugs 0.000 description 1
229940003382 depo-medrol Drugs 0.000 description 1
229960003662 desonide Drugs 0.000 description 1
229940076379 desowen Drugs 0.000 description 1
229960002593 desoximetasone Drugs 0.000 description 1
229960003657 dexamethasone acetate Drugs 0.000 description 1
229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229960002124 diflorasone diacetate Drugs 0.000 description 1
229940079920 digestives acid preparations Drugs 0.000 description 1
230000010339 dilation Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000008406 drug-drug interaction Effects 0.000 description 1
229940073541 econopred Drugs 0.000 description 1
230000001819 effect on gene Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
229940073610 elocon Drugs 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000003344 environmental pollutant Substances 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
208000003401 eosinophilic granuloma Diseases 0.000 description 1
201000009580 eosinophilic pneumonia Diseases 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003090 exacerbative effect Effects 0.000 description 1
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
208000024711 extrinsic asthma Diseases 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
238000009093 first-line therapy Methods 0.000 description 1
230000003890 fistula Effects 0.000 description 1
229940085863 florone Drugs 0.000 description 1
229960004511 fludroxycortide Drugs 0.000 description 1
XSFJVAJPIHIPKU-XWCQMRHXSA-N flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
229960001347 fluocinolone acetonide Drugs 0.000 description 1
229960000785 fluocinonide Drugs 0.000 description 1
229960003336 fluorocortisol acetate Drugs 0.000 description 1
229960001048 fluorometholone Drugs 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000011331 genomic analysis Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229960002383 halcinonide Drugs 0.000 description 1
229940028332 halog Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007686 hepatotoxicity Effects 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
231100000086 high toxicity Toxicity 0.000 description 1
238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000052620 human IL10 Human genes 0.000 description 1
229950000785 hydrocortisone phosphate Drugs 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
208000018875 hypoxemia Diseases 0.000 description 1
208000013397 idiopathic acute eosinophilic pneumonia Diseases 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000008938 immune dysregulation Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000027138 indeterminate colitis Diseases 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000007689 inspection Methods 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000003601 intercostal effect Effects 0.000 description 1
208000024710 intermittent asthma Diseases 0.000 description 1
210000005206 intestinal lamina propria Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
108010050180 kallistatin Proteins 0.000 description 1
229940063199 kenalog Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000002523 lectin Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
229940071337 locoid Drugs 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960001011 medrysone Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
229960001293 methylprednisolone acetate Drugs 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960002744 mometasone furoate Drugs 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000002969 morbid Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000003562 morphometric effect Effects 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
210000004296 naive t lymphocyte Anatomy 0.000 description 1
229940063121 neoral Drugs 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
235000015816 nutrient absorption Nutrition 0.000 description 1
208000007892 occupational asthma Diseases 0.000 description 1
235000019645 odor Nutrition 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000001734 parasympathetic effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
238000009527 percussion Methods 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000012466 permeate Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
208000007578 phototoxic dermatitis Diseases 0.000 description 1
231100000018 phototoxicity Toxicity 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960005414 pirbuterol Drugs 0.000 description 1
201000003144 pneumothorax Diseases 0.000 description 1
231100000719 pollutant Toxicity 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
230000030786 positive chemotaxis Effects 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229940063566 proventil Drugs 0.000 description 1
229940072266 pulmicort Drugs 0.000 description 1
230000009325 pulmonary function Effects 0.000 description 1
210000004879 pulmonary tissue Anatomy 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
230000001739 rebound effect Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
210000001533 respiratory mucosa Anatomy 0.000 description 1
210000003019 respiratory muscle Anatomy 0.000 description 1
230000036387 respiratory rate Effects 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
201000007916 right bundle branch block Diseases 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
210000002955 secretory cell Anatomy 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
208000004003 siderosis Diseases 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
239000002002 slurry Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
230000029547 smooth muscle hypertrophy Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
MQRFYYBWKRACSJ-UHFFFAOYSA-N sodium;[2-(9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl)-2-oxoethyl] dihydrogen phosphate Chemical compound [Na+].C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)COP(O)(O)=O)(O)C1(C)CC2O MQRFYYBWKRACSJ-UHFFFAOYSA-N 0.000 description 1
MQRFYYBWKRACSJ-WKSAPEMMSA-L sodium;[2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate Chemical compound [Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O MQRFYYBWKRACSJ-WKSAPEMMSA-L 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
229940087854 solu-medrol Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960002211 sulfapyridine Drugs 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
229940099293 synalar Drugs 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229950001362 tebutate Drugs 0.000 description 1
229940001017 temovate Drugs 0.000 description 1
230000028016 temperature homeostasis Effects 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
229940035306 topicort Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
229960004320 triamcinolone diacetate Drugs 0.000 description 1
229960004221 triamcinolone hexacetonide Drugs 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
230000009723 vascular congestion Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
229940070384 ventolin Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
229940053761 westcort Drugs 0.000 description 1